Literature DB >> 2882282

Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations.

C Stibe, A Lees, G Stern.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2882282     DOI： 10.1016/s0140-6736(87)91660-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

3.  Rectal apomorphine: a new treatment modality in Parkinson's disease.

Authors:  T Van Laar; E N Jansen; A W Essink; W J Rutten; C Neef
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

Review 4.  High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review.

Authors:  R Carron; V Fraix; C Maineri; E Seigneuret; B Piallat; P Krack; P Pollak; A L Benabid; Stéphan Chabardès
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

Review 5.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

6.  Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in parkinsonian squirrel monkeys.

Authors:  N M Rupniak; S J Tye; C A Jennings; A E Loper; J V Bondi; M Hichens; S D Iversen; S M Stahl
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

7.  Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.

Authors:  R van der Geest; T van Laar; J M Gubbens-Stibbe; H E Boddé; M Danhof
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

8.  Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.

Authors:  N R Cutler; S A Reines; L F McLean; J J Sramek; A G Porras; E L Hand
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

9.  Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.

Authors:  E Sam; A P Jeanjean; J M Maloteaux; N Verbeke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jan-Mar       Impact factor: 2.441

10.  Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

Authors:  K Pietz; P Hagell; P Odin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.